Acute liver failure secondary prevention: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Acute liver failure}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==References== {{...")
 
 
(7 intermediate revisions by 4 users not shown)
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Acute liver failure}}
{{Acute liver failure}}
Please help WikiDoc by adding content here. It's easy!  Click  [[Help:How_to_Edit_a_Page|here]] to learn about editing.  
{{CMG}} {{AE}}
 
 
==Overview==
Effective measures for secondary prevention of acute liver failure include management of chronic liver disease and its complications. In patients with resolved [[hepatitis B]] infection, [[Antiviral Therapy|antiviral prophylaxis]] can be considered in the patients who have a risk of reactivation such as [[immunosuppressed]] individuals.
 
==Secondary Prevention==
Effective measures for secondary prevention of acute liver failure include:<ref name="pmid27311622">{{cite journal| author=Karvellas CJ, Cardoso FS, Gottfried M, Reddy KR, Hanje AJ, Ganger D et al.| title=HBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death. | journal=Clin Gastroenterol Hepatol | year= 2017 | volume= 15 | issue= 1 | pages= 113-122 | pmid=27311622 | doi=10.1016/j.cgh.2016.06.008 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27311622  }} </ref>
 
* Management of [[chronic liver disease]] appropriately.
* Management of active complications of the chronic liver disease.
* In patients with resolved [[hepatitis B infection]], [[antiviral]] [[prophylaxis]] can be considered in the patients who have risk of reactivation such as [[immunosuppressed]] individuals.


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}


[[Category:Needs content]]
[[Category:Hepatology]]
[[Category:Gastroenterology]]
 
{{WH}}
{{WS}}

Latest revision as of 18:36, 14 December 2017

Acute liver failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute Liver Failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute liver failure secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute liver failure secondary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute liver failure secondary prevention

CDC on Acute liver failure secondary prevention

Acute liver failure secondary prevention in the news

Blogs on Acute liver failure secondary prevention

Directions to Hospitals Treating Acute liver failure

Risk calculators and risk factors for Acute liver failure secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief:


Overview

Effective measures for secondary prevention of acute liver failure include management of chronic liver disease and its complications. In patients with resolved hepatitis B infection, antiviral prophylaxis can be considered in the patients who have a risk of reactivation such as immunosuppressed individuals.

Secondary Prevention

Effective measures for secondary prevention of acute liver failure include:[1]

References

  1. Karvellas CJ, Cardoso FS, Gottfried M, Reddy KR, Hanje AJ, Ganger D; et al. (2017). "HBV-Associated Acute Liver Failure After Immunosuppression and Risk of Death". Clin Gastroenterol Hepatol. 15 (1): 113–122. doi:10.1016/j.cgh.2016.06.008. PMID 27311622.

Template:WH Template:WS